iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020– EOS-448 is being investigated in a Phase 1/2a clinical trial in advanced solid tumors and the dose escalation portion of the trial was initiated in February 2020 – – EOS-448 has shown potent antitumor activity and a favourable tolerability profile in preclinical studies – Cambridge, MA and
btn News Archive
Disclaimer. This page contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management’s plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward looking statements. iTeos assumes no obligation to update any forward-looking statements [on this page/in this press release] in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.